A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...

GLP-1 RA medications safe and very effective for treating obesity in adults without diabetes Data also shows some very promising options that are not yet FDA approved Abstract: https://www ...

Researchers analyzed data from the US Collaborative Network of TriNetX of 140,308 patients with T2D who were initiated on tirzepatide or a GLP-1 RA between June 1, 2022, and June 30, 2023.

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose ...

Key factors that impact long-term weight loss in patients prescribed GLP-1 RA medications. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2024 / 09 / 240913131119.htm ...

The researchers observed an increase in the number of adolescents and young adults with GLP-1 RA dispensing, from 8722 to 60,567 (594.4%), between 2020 and 2023.

References: Ashruf OS, Hundal J, Mushtaq A, Kaelber DC, Anwer F, Singh A. Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists. JAMA Netw Open. 2025;8(3 ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. (HealthDay News) — For patients with ischemic stroke, sodium-glucose ...

GLP-1 RA users also lost a few pounds after 6 months of treatment (204.17 lb from 206.04 lb at baseline), while those not on these agents gained a significant amount of weight (180.96 lb at ...